Brokerages Set Savara Inc. (NASDAQ:SVRA) PT at $9.13

Shares of Savara Inc. (NASDAQ:SVRA) have received an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $9.1250.

Several research analysts recently commented on the company. Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. William Blair set a $10.00 target price on Savara in a research note on Monday, March 16th. HC Wainwright reissued a “buy” rating on shares of Savara in a research note on Monday, March 16th. Finally, Oppenheimer assumed coverage on Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 target price for the company.

Savara Trading Down 2.4%

Shares of NASDAQ SVRA opened at $4.91 on Friday. Savara has a twelve month low of $1.89 and a twelve month high of $7.01. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17. The stock has a fifty day simple moving average of $5.34 and a 200-day simple moving average of $5.49. The stock has a market capitalization of $1.01 billion, a PE ratio of -8.77 and a beta of 0.28.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). On average, equities analysts forecast that Savara will post -0.56 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SVRA. Polar Capital Holdings Plc acquired a new position in Savara during the 4th quarter worth $50,086,000. RTW Investments LP acquired a new position in Savara during the 4th quarter worth $35,893,000. VR Adviser LLC grew its stake in Savara by 172.7% during the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after purchasing an additional 5,626,624 shares in the last quarter. Marshall Wace LLP acquired a new position in Savara during the 4th quarter worth $27,496,000. Finally, Spruce Street Capital LP purchased a new stake in Savara during the 4th quarter worth about $14,539,000. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.